Table 2

Pooled analysis and stratified analyses of SSc patients and healthy controls for rs10744676 genetic variant, located in the KCNA5 gene

Genotype, n (%)

Allele test



Subgroup (n)

C/C

C/T

T/T

MAF (%)

PMH

OR (95% CI)

PBD


Controls (n = 2,690)

37 (1.38)

597 (22.19)

2,056 (76.43)

12.47

SSc (n = 2,343)

43 (1.84)

471 (20.10)

1,829 (78.06)

11.89

0.49

0.96 (0.85-1.08)

0.53

lcSSc (n = 1,642)

31 (1.89)

327 (19.91)

1,284 (78.20)

11.85

0.48

0.95 (0.83-1.09)

0.63

dcSSc (n = 701)

12 (1.71)

144 (20.54)

545 (77.75)

11.98

0.80

0.98 (0.81-1.17)

0.59

ACA+ (n = 931)

18 (1.93)

197 (21.16)

716 (76.91)

12.51

0.49

1.06 (0.90-1.24)

0.96

ATA+ (n = 568)

8 (1.41)

117 (20.60)

443 (77.99)

11.71

0.85

0.98 (0.80-1.20)

0.94

Fib+ (n = 771)

14 (1.82)

154 (19.97)

603 (78.21)

11.80

0.34

0.92 (0.77-1.09)

0.92

PAH+ (n = 179)

2 (1.12)

37 (20.67)

140 (78.21)

11.45

0.44

0.88 (0.63-1.23)

0.70


MAF, minor allele frequency; PMH, Mantel-Haenszel test under fixed-effect P values. Controls are used as reference for all comparisons, and P values have been calculated for the allelic model. OR, odds ratio for the minor allele; 95% CI, 95% confidence interval; SSc, systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; ACA+, anti-centromere autoantibody-positive patient; ATA+, anti-topoisomerase autoantibody-positive patient; Fib+, lung fibrosis-positive patient (HRCT); PAH+, pulmonary arterial hypertension-positive patients (right-heart catheterization).

Bossini-Castillo et al. Arthritis Research & Therapy 2012 14:R273   doi:10.1186/ar4124

Open Data